Plasma Tau Biomarkers and Alzheimer's Cognition

A study of 123 participants has identified specific plasma tau biomarkers, particularly the p-tau217/tau212–221 ratio, as strong indicators of Alzheimer's disease pathology and cognitive decline. These blood-based tests offer a less invasive method for monitoring disease progression.
Why it matters
Advancements in blood-based biomarkers could revolutionize Alzheimer's diagnostics by replacing more invasive or expensive procedures.
PLASMA tau biomarkers, particularly phosphorylated tau217 and its ratio to non-phosphorylated tau, demonstrated strong associations with cognitive performance in a study involving 123 participants who underwent post-mortem assessment for Alzheimer’s disease pathology.
The findings highlighted the potential of blood-based biomarkers to reflect clinical features of Alzheimer’s disease and support future symptom monitoring.
Researchers investigated associations between phosphorylated and non-phosphorylated tau species measured in blood samples collected during life and neuropsychological outcomes in participants with subsequent brain donation.
The cross-sectional study included 123 participants from the Boston University Alzheimer’s Disease Research Center who underwent neuropsychological testing during life and neuropathological assessment following death.
Alzheimer’s disease pathology was evaluated using National Institute on Aging–Reagan criteria.
The mean age at blood collection was 78.17 years (standard deviation: 8.55), while 55 participants (44.7%) were female.
Researchers used immunoprecipitation mass spectrometry to measure six phosphorylated tau species, including p-tau181, p-tau199, p-tau202, p-tau205, p-tau217 and p-tau231.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in